Evidence has emerged during the past few years that demonstrates the existence of an endogenous cannabinoid system in the brain. This system consists of a G-protein coupled receptor (CB1), several potential effector systems, and the endogenous ligand anandamide. An additional cannabinoid receptor (CB2) is found primarily in macrophages. The goal of the proposed research is to identify additional receptors and/or mechanisms through which cannabinoids produce their behavioral effects and establish the physiological role of the endogenous system in brain. Our current findings suggest that selective analogs can be developed that do not produce the full array of cannabinoid effects. We will continue developing highly potent novel agonists to fully explore the structure-activity relationships, as well as to produce selectivity for behavioral effects and for CB1 and CB2 receptors. Efforts will be made to develop additional competitive antagonists as well as irreversible antagonists for both CB1 and CB2 receptors. These analogs will be evaluated in CB1 and CB2 receptor binding assays, several mouse pharmacological assays, rat drug discrimination, and for inhibition of macrophage function. A major objective is to determine what role the endogenous cannabinoid system plays in the development of tolerance and dependence. It has been shown that the development of tolerance is associated with receptor down-regulation and elevated CB1 mRNA levels in cerebellum of mice. Studies are proposed for determining whether similar changes occur in cerebral cortex, hippocampus and striatum. Further evaluation of tolerance in selected brain areas will include measurement of receptor levels, determination of receptor sequestration, MAP kinase activity and levels of krox-24 and CB1 mRNA. The recent discovery of a specific cannabinoid antagonist allowed us to develop for the first time a model of cannabinoid dependence in both mice and rats. We will fully characterize this model regarding the dose of delta9-THC and the frequency of administration that is required for development of dependence. The time required for recovery from dependence will be established and efforts will be made to detect abrupt withdrawal. The biochemical changes observed in the development of tolerance will also be examined during the development of and recovery from dependence. Additionally, CREB levels will be measured in dependent animals, since it has been implicated in the development of dependence for several classes of compounds.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37DA003672-16
Application #
2897701
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Rapaka, Rao
Project Start
1984-09-01
Project End
2002-07-31
Budget Start
1999-08-01
Budget End
2000-07-31
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Mitjavila, Jose; Yin, Danielle; Kulkarni, Pushkar M et al. (2018) Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. Pharmacol Res 129:475-481
Barrus, Daniel G; Lefever, Timothy W; Wiley, Jenny L (2018) Evaluation of reinforcing and aversive effects of voluntary ?9-tetrahydrocannabinol ingestion in rats. Neuropharmacology 137:133-140
Kevin, Richard C; Lefever, Timothy W; Snyder, Rodney W et al. (2018) Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. Drug Test Anal 10:137-147
Marusich, Julie A; Wiley, Jenny L; Lefever, Timothy W et al. (2018) Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology 134:73-81
Wiley, Jenny L; Lefever, Timothy W; Marusich, Julie A et al. (2017) Comparison of the discriminative stimulus and response rate effects of ?9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats. Drug Alcohol Depend 172:51-59
Gamage, Thomas F; Farquhar, Charlotte E; Lefever, Timothy W et al. (2017) The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators. Neuropharmacology 125:365-375
Nguyen, Thuy; German, Nadezhda; Decker, Ann M et al. (2017) Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution. J Med Chem 60:7410-7424
Lefever, Timothy W; Marusich, Julie A; Thomas, Brian F et al. (2017) Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Subst Abuse 11:1178221817701739
Lefever, Timothy W; Lee, Youn O K; Kovach, Alexander L et al. (2017) Delivery of nicotine aerosol to mice via a modified electronic cigarette device. Drug Alcohol Depend 172:80-87
Barrus, Daniel G; Capogrossi, Kristen L; Cates, Sheryl C et al. (2016) Tasty THC: Promises and Challenges of Cannabis Edibles. Methods Rep RTI Press 2016:

Showing the most recent 10 out of 230 publications